Endogun Medical Systems Ltd. announced this week that is has launched a human clinical study for the treatment of Pelvic Organ Prolapse, which occurs in women often following births or significant weight loss, and develops as a result of weakening of the pelvic muscles which support internal organs. The company claims its solution has significant advantages over what is currently available and will increase the safety and overall costs associated with prolapse repair.
Kiryat Shmona-based Endogun manufactures products for minimally-invasive fastening of soft-tissue, and has completed two rounds of financing for its prolapse product, led by Pontifax Funds, founded by Teva Pharmaceutical Industries CEO Eli Hurvitz.
Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>